## THE GENERAL ASSEMBLY OF PENNSYLVANIA

## SENATE BILL No. 391 Session of 2019

INTRODUCED BY GORDNER, SCARNATI, FOLMER, BAKER, HUTCHINSON, YUDICHAK, HAYWOOD AND PITTMAN, MARCH 5, 2019

SENATOR TOMLINSON, CONSUMER PROTECTION AND PROFESSIONAL LICENSURE, AS AMENDED, SEPTEMBER 22, 2020

## AN ACT

1	Amending the act of June 6, 1980 (P.L.197, No.57), entitled "An-	<
2	act regulating the licensure and practice of optometry,	
3	making repeals and providing penalties," further providing	
4	for definitions, for approval of drugs, for exemptions and	
5	exceptions and for violations and penalties; and providing	
6	for insurance billing codes.	
7	AMENDING THE ACT OF JUNE 6, 1980 (P.L.197, NO.57), ENTITLED "AN	<
8	ACT REGULATING THE LICENSURE AND PRACTICE OF OPTOMETRY,	
9	MAKING REPEALS AND PROVIDING PENALTIES," FURTHER PROVIDING	
10	FOR DEFINITIONS, FOR APPROVAL OF DRUGS, FOR EXEMPTIONS AND	
11	EXCEPTIONS AND FOR VIOLATIONS AND PENALTIES.	
12	The General Assembly of the Commonwealth of Pennsylvania	
13	hereby enacts as follows:	
14	Section 1. The definitions of "examination and diagnosis,"	<
15	"optometrist" and "practice of optometry" in section 2 of the	
16	act of June 6, 1980 (P.L.197, No.57), known as the Optometric	
17	Practice and Licensure Act, are amended to read:	
18	Section 2. Definitions.	
19	The following words and phrases when used in this act shall	
20	have, unless the context clearly indicates otherwise, the	
21	meanings given to them in this section:	
22	* * *	

1	"Examination and diagnosis." Any examination or diagnostic
2	means or method compatible with optometric education and
3	professional competence. The term shall encompass the use of
4	pharmaceutical agents approved by the Food and Drug
5	Administration and published in the Code of Federal Regulations
6	for diagnostic purposes [classified as], including miotics,
7	mydriatics, cycloplegics, topical anesthetics and dyes when
8	applied topically to the eye, [which pharmaceutical agents shall-
9	be approved by the Secretary of Health as provided in section-
10	4.3 and,] subject to the rules and regulations of the board,
11	provided however that with respect to optometrists licensed
12	before March 1, 1974, only such optometrists who have
13	satisfactorily completed a course in pharmacology as it applies
14	to optometry, with particular emphasis on the [topical]
15	application of diagnostic pharmaceutical agents to the eye,
16	approved by the board shall be permitted to use diagnostic-
17	pharmaceutical agents [topically] in the practice of optometry.
18	* * *
19	"Optometrist." Any person who, following formal and
20	recognized training in the art and science of optometry has
21	received a doctor of optometry degree from an accredited
22	institution and is qualified to seek or has acquired a license
23	to practice the profession of optometry. An optometrist shall be
24	identified either by "Doctor of Optometry," ["O.D.," or "Dr."
25	followed by "Optometrist."] <u>"O.D." or "Doctor."</u>
26	"Practice of optometry."
27	(1) The use of any and all means or methods for the
28	examination, diagnosis, prevention and treatment of all
29	conditions [of] <u>affecting</u> the human visual system [and shall-
30	include the examination for, and adapting and fitting of, any-

20190SB0391PN2009

- 2 -

1	and all kinds and types of lenses including contact lenses.],
2	including all conditions of the human eye and adnexa
3	applicable to this act. The term shall include:
4	(i) The examination for, and adapting and fitting
5	of, any and all kinds and types of lenses, including
6	contact lenses.
7	(ii) The administration and prescription of all
8	legend and nonlegend drugs, by any means, methods or
9	delivery systems, approved by the board in section 4.3
10	for the treatment of diseases and conditions affecting
11	the eye and adnexa, including codeine and hydrocodone
12	combinations which were reclassified from Schedule III to
13	Schedule II prior to the effective date of this
14	subparagraph. The prescription of Schedule II controlled
15	substances containing codeine and hydrocodone
16	combinations may not exceed a 72 hour supply.
17	(iii) The removal of superficial foreign bodies.
18	(iv) The draining of superficial cysts.
19	(v) Epinephrine auto-injectors for anaphylaxis.
20	(vi) The ordering and interpretation of angiography
21	via noninvasive imaging, including, but not limited to,
22	light wave imaging and other imaging tests.
23	(vii) The treatment of glaucoma.
24	[(2) The administration and prescription of legend and
25	nonlegend drugs as approved by the Secretary of Health as
26	provided in section 4.3 for treatment of the eye, the
27	eyelids, the lacrimal system and the conjunctiva and the
28	removal of superficial foreign bodies from the ocular surface-
29	and adnexa so long as treatment of diseases or conditions of
30	the visual system, other than glaucoma, as authorized under-
201909	SB0391PN2009 - 3 -

20190SB0391PN2009

- 3 -

1	this paragraph shall not continue beyond six weeks from the
2	initiation of treatment unless the prescribing optometrist
3	documents consultation with a licensed physician. As used in
4	this paragraph, the initiation of treatment may, but need
5	not, include the prescription or administration of
6	pharmaceutical agents for therapeutic purposes.
7	(3) The term shall not include:
8	(i) surgery, including, but not limited to, laser-
9	surgery; the use of lasers for therapeutic purposes; and
10	the use of injections in the treatment of ocular disease;
11	(ii) the use of Schedule I and Schedule II
12	controlled substances;
13	(iii) treatment of systemic disease; and
14	(iv) the treatment of glaucoma, except that
15	optometrists may use all topical pharmaceutical agents in
16	the treatment of primary open angle glaucoma, exfoliation
16 17	the treatment of primary open angle glaucoma, exfoliation glaucoma and pigmentary glaucoma.]
17	glaucoma and pigmentary glaucoma.]
17 18	glaucoma and pigmentary glaucoma.] (4) The term shall not include:
17 18 19	glaucoma and pigmentary glaucoma.] (4) The term shall not include: (i) Surgery with a scalpel or scissors, refractive
17 18 19 20	glaucoma and pigmentary glaucoma.] (4) The term shall not include: (i) Surgery with a scalpel or scissors, refractive or therapeutic surgery with a laser and surgery with a
17 18 19 20 21	<pre>glaucoma and pigmentary glaucoma.] (4) The term shall not include:     (i) Surgery with a scalpel or scissors, refractive     or therapeutic surgery with a laser and surgery with a     <u>CryoProbe.</u></pre>
17 18 19 20 21 22	<pre>glaucoma and pigmentary glaucoma.] (4) The term shall not include:     (i) Surgery with a scalpel or scissors, refractive     or therapeutic surgery with a laser and surgery with a     CryoProbe.     (ii) Injection into the globe.</pre>
17 18 19 20 21 22 23	<pre>glaucoma and pigmentary glaucoma.] (4) The term shall not include: (i) Surgery with a scalpel or scissors, refractive or therapeutic surgery with a laser and surgery with a <u>CryoProbe.</u> (ii) Injection into the globe. (iii) The use of Schedule I and Schedule II</pre>
17 18 19 20 21 22 23 24	<pre>glaucoma and pigmentary glaucoma.] (4) The term shall not include:     (i) Surgery with a scalpel or scissors, refractive     or therapeutic surgery with a laser and surgery with a     CryoProbe.     (ii) Injection into the globe.     (iii) The use of Schedule I and Schedule II     controlled substances, except for the use of codeine and</pre>
17 18 19 20 21 22 23 24 25	<pre>glaucoma and pigmentary glaucoma.] (4) The term shall not include: (i) Surgery with a scalpel or scissors, refractive or therapeutic surgery with a laser and surgery with a CryoProbe. (ii) Injection into the globe. (iii) The use of Schedule I and Schedule II controlled substances, except for the use of codeine and hydrocodone combinations which were reclassified from</pre>
17 18 19 20 21 22 23 24 25 26	<pre>glaucoma and pigmentary glaucoma.] (4) The term shall not include: (i) Surgery with a scalpel or scissors, refractive or therapeutic surgery with a laser and surgery with a CryoProbe. (ii) Injection into the globe. (iii) The use of Schedule I and Schedule II controlled substances, except for the use of codeine and hydrocodone combinations which were reclassified from Schedule III to Schedule II prior to the effective date</pre>
17 18 19 20 21 22 23 24 25 26 27	<pre>glaucoma and pigmentary glaucoma.] (4) The term shall not include: (i) Surgery with a scalpel or scissors, refractive or therapeutic surgery with a laser and surgery with a GryoProbe. (ii) Injection into the globe. (iii) The use of Schedule I and Schedule II controlled substances, except for the use of codeine and hydrocodone combinations which were reclassified from Schedule III to Schedule II prior to the effective date of this subparagraph and any drugs approved by the board</pre>

1 read:

2	Section 4.3. Approval of drugs.
3	Drugs shall be approved as follows:
4	(1) All drugs currently approved by the Secretary of
5	Health and in use in the practice of optometry on the
6	effective date of this section shall be deemed approved under
7	this section.
8	(2) Within 90 days of the effective date of this
9	section, the board shall submit a list of drugs authorized
10	under this act to the Secretary of Health, who, in-
11	consultation with the Physician General, shall approve or-
12	disapprove for good cause each drug. Upon failure of the
13	Secretary of Health to act within 90 days of receipt of the
14	list of drugs, the drugs shall be deemed approved for use-
15	under this act.
16	(3) The State Board of Optometry shall provide the
17	Secretary of Health with lists of additional drugs for use
18	under this act after such drugs are approved by the Food and
19	Drug Administration, as published in the Code of Federal
20	Regulations. The Secretary of Health, in consultation with
21	the Physician General, shall approve or disapprove for good-
22	<del>cause any such drug within 90 days of the receipt of the</del>
23	list. Upon failure of the Secretary of Health to act within-
24	90 days, the drugs shall be deemed approved for use under-
25	this act.]
26	(4) On and after the effective date of this paragraph,
27	the board may approve drugs for use in the practice of
28	optometry after the drugs are approved by the Food and Drug
29	Administration, as published in the Code of Federal
30	Regulations.
0.04	

20190SB0391PN2009

- 5 -

1 Section 6. Exemptions and exceptions.

## 2 \* \* \*

3	(b) The board shall permit externs, who are [fourth year]
4	optometric students, to perform procedures and tests for the
5	sole purpose of instruction and experience under the direct
6	supervision and control of an optometrist licensed in this
7	Commonwealth. Nothing contained in this act shall be construed
8	to entitle an extern to practice optometry.
9	* * *
10	Section 3. Section 8(a) of the act is amended by adding a
11	paragraph to read:
12	Section 8. Violations and penalties.
13	<del>(a) * * *</del>
14	(4) It is unlawful for an optometrist to advertise a
15	service prohibited under this act. A person convicted of
16	violating this paragraph commits a summary offense and shall,
17	for a first offense, be subject to a fine of not more than
18	\$500. For a second or subsequent violation, the board may
19	impose a suspension of the person's license for up to 30
20	days, in addition to the fine.
21	* * *
22	Section 4. The act is amended by adding a section to read:
23	Section 10.1. Insurance billing codes.
24	An insurance billing code may not be used to define or
25	interpret a procedure performed by an optometrist as surgery.
26	Section 5. This act shall take effect in 60 days.
27	SECTION 1. THE DEFINITIONS OF "EXAMINATION AND DIAGNOSIS" <
28	AND "PRACTICE OF OPTOMETRY" IN SECTION 2 OF THE ACT OF JUNE 6,
29	1980 (P.L.197, NO.57), KNOWN AS THE OPTOMETRIC PRACTICE AND
30	LICENSURE ACT, ARE AMENDED TO READ:
201	90SB0391PN2009 - 6 -

20190SB0391PN2009

- 6 -

1 SECTION 2. DEFINITIONS.

2 THE FOLLOWING WORDS AND PHRASES WHEN USED IN THIS ACT SHALL
3 HAVE, UNLESS THE CONTEXT CLEARLY INDICATES OTHERWISE, THE
4 MEANINGS GIVEN TO THEM IN THIS SECTION:

5 \* \* \*

"EXAMINATION AND DIAGNOSIS." ANY EXAMINATION OR DIAGNOSTIC 6 7 MEANS OR METHOD COMPATIBLE WITH OPTOMETRIC EDUCATION AND 8 PROFESSIONAL COMPETENCE. THE TERM SHALL ENCOMPASS THE USE OF 9 TOPICAL AND ORAL PHARMACEUTICAL AGENTS APPROVED BY THE BOARD AS 10 PROVIDED IN SECTION 4.3 FOR DIAGNOSTIC PURPOSES [CLASSIFIED AS], INCLUDING MIOTICS, MYDRIATICS, CYCLOPLEGICS, TOPICAL ANESTHETICS 11 AND DYES WHEN APPLIED TOPICALLY TO THE EYE, [WHICH 12 13 PHARMACEUTICAL AGENTS SHALL BE APPROVED BY THE SECRETARY OF 14 HEALTH AS PROVIDED IN SECTION 4.3 AND, ] SUBJECT TO THE RULES AND REGULATIONS OF THE BOARD, PROVIDED HOWEVER THAT WITH RESPECT TO 15 16 OPTOMETRISTS LICENSED BEFORE MARCH 1, 1974, ONLY SUCH OPTOMETRISTS WHO HAVE SATISFACTORILY COMPLETED A COURSE IN 17 18 PHARMACOLOGY AS IT APPLIES TO OPTOMETRY, WITH PARTICULAR 19 EMPHASIS ON THE TOPICAL APPLICATION OF DIAGNOSTIC PHARMACEUTICAL 20 AGENTS TO THE EYE, APPROVED BY THE BOARD SHALL BE PERMITTED TO USE DIAGNOSTIC PHARMACEUTICAL AGENTS TOPICALLY IN THE PRACTICE 21 22 OF OPTOMETRY.

23 \* \* \*

24 "PRACTICE OF OPTOMETRY."

(1) THE USE OF ANY AND ALL MEANS OR METHODS FOR THE
EXAMINATION, DIAGNOSIS AND TREATMENT OF <u>ALL</u> CONDITIONS OF THE
HUMAN VISUAL SYSTEM [AND SHALL INCLUDE THE EXAMINATION FOR,
AND ADAPTING AND FITTING OF, ANY AND ALL KINDS AND TYPES OF
LENSES INCLUDING CONTACT LENSES]. <u>THE TERM SHALL INCLUDE:</u>
(1) THE EXAMINATION FOR, AND ADAPTING AND FITTING

- 7 -

1 OF, ANY AND ALL KINDS AND TYPES OF LENSES, INCLUDING 2 CONTACT LENSES. 3 (II) THE ADMINISTRATION AND PRESCRIPTION OF ALL LEGEND AND NONLEGEND DRUGS, EITHER BY TOPICAL OR ORAL 4 ROUTES OF ADMINISTRATION, APPROVED BY THE BOARD IN 5 6 SECTION 4.3 FOR THE TREATMENT OF THE EYE, THE EYELIDS, 7 THE LACRIMAL SYSTEM AND THE CONJUNCTIVA, INCLUDING 8 CODEINE AND HYDROCODONE COMBINATIONS, SO LONG AS THE 9 TREATMENT OF DISEASES OR CONDITIONS OF THE VISUAL SYSTEM, 10 OTHER THAN GLAUCOMA, DRY EYES OR ALLERGIES, AS AUTHORIZED UNDER THIS PARAGRAPH SHALL NOT CONTINUE BEYOND SIX WEEKS 11 FROM THE INITIATION OF TREATMENT UNLESS THE PRESCRIBING 12 13 OPTOMETRIST DOCUMENTS CONSULTATION WITH A LICENSED 14 PHYSICIAN. AS USED IN THIS PARAGRAPH, THE INITIATION OF TREATMENT MAY, BUT NEED NOT, INCLUDE THE PRESCRIPTION OR 15 16 ADMINISTRATION OF PHARMACEUTICAL AGENTS FOR THERAPEUTIC PURPOSES. THE PRESCRIPTION OF SCHEDULE II CONTROLLED 17 18 SUBSTANCES CONTAINING CODEINE AND HYDROCODONE COMBINATIONS MAY NOT EXCEED A 72-HOUR SUPPLY. 19 (III) THE REMOVAL OF SUPERFICIAL FOREIGN BODIES FROM 20 21 THE OCULAR SURFACE OR ADNEXA. 22 (IV) EPINEPHRINE AUTO-INJECTORS FOR ANAPHYLAXIS. 23 (V) THE ORDERING AND INTERPRETATION OF ANGIOGRAPHY VIA NONINVASIVE IMAGING, WHICH SHALL ONLY INCLUDE OPTICAL 24 25 COHERENCE TOMOGRAPHY. 26 (VI) THE ADMINISTRATION AND PRESCRIPTION OF ALL 27 LEGEND AND NONLEGEND DRUGS APPROVED BY THE BOARD UNDER 28 SECTION 4.3 FOR THE TREATMENT OF GLAUCOMA. 29 (2) THE ADMINISTRATION AND PRESCRIPTION OF LEGEND AND NONLEGEND DRUGS AS APPROVED BY THE SECRETARY OF HEALTH AS 30

- 8 -

1	PROVIDED IN SECTION 4.3 FOR TREATMENT OF THE EYE, THE
2	EYELIDS, THE LACRIMAL SYSTEM AND THE CONJUNCTIVA AND THE
3	REMOVAL OF SUPERFICIAL FOREIGN BODIES FROM THE OCULAR SURFACE
4	AND ADNEXA SO LONG AS TREATMENT OF DISEASES OR CONDITIONS OF
5	THE VISUAL SYSTEM, OTHER THAN GLAUCOMA, AS AUTHORIZED UNDER
6	THIS PARAGRAPH SHALL NOT CONTINUE BEYOND SIX WEEKS FROM THE
7	INITIATION OF TREATMENT UNLESS THE PRESCRIBING OPTOMETRIST
8	DOCUMENTS CONSULTATION WITH A LICENSED PHYSICIAN. AS USED IN
9	THIS PARAGRAPH, THE INITIATION OF TREATMENT MAY, BUT NEED
10	NOT, INCLUDE THE PRESCRIPTION OR ADMINISTRATION OF
11	PHARMACEUTICAL AGENTS FOR THERAPEUTIC PURPOSES.
12	(3) THE TERM SHALL NOT INCLUDE:
13	(I) SURGERY, INCLUDING, BUT NOT LIMITED TO, LASER
14	SURGERY; THE USE OF LASERS FOR THERAPEUTIC PURPOSES; AND
15	THE USE OF INJECTIONS IN THE TREATMENT OF OCULAR DISEASE;
16	(II) THE USE OF SCHEDULE I AND SCHEDULE II
17	CONTROLLED SUBSTANCES;
18	(III) TREATMENT OF SYSTEMIC DISEASE; AND
19	(IV) THE TREATMENT OF GLAUCOMA, EXCEPT THAT
20	OPTOMETRISTS MAY USE ALL TOPICAL PHARMACEUTICAL AGENTS IN
21	THE TREATMENT OF PRIMARY OPEN ANGLE GLAUCOMA, EXFOLIATION
22	GLAUCOMA AND PIGMENTARY GLAUCOMA.]
23	(4) THE TERM SHALL NOT INCLUDE:
24	(I) SURGERY, INCLUDING, BUT NOT LIMITED TO,
25	DIAGNOSTIC, EXPLORATORY, PALLIATIVE, THERAPEUTIC,
26	REHABILITATIVE, COSMETIC, RECONSTRUCTIVE, REFRACTIVE,
27	LIGHT-BASED OR LASER SURGERY; OR THE USE OF LASERS FOR
28	THERAPEUTIC PURPOSES.
29	(II) INJECTIONS, OTHER THAN THE USE OF EPINEPHRINE
30	AUTO-INJECTORS FOR ANAPHYLAXIS.

- 9 -

1 (III) THE USE OF SCHEDULE I AND SCHEDULE II CONTROLLED SUBSTANCES, EXCEPT FOR THE USE OF CODEINE AND 2 3 HYDROCODONE COMBINATIONS. (IV) THE PREVENTION AND TREATMENT OF SYSTEMIC 4 DISEASE. 5 \* \* \* 6 7 SECTION 2. SECTIONS 4.3 AND 6(B) OF THE ACT ARE AMENDED TO 8 READ: 9 SECTION 4.3. APPROVAL OF DRUGS. 10 DRUGS SHALL BE APPROVED AS FOLLOWS: (1) ALL DRUGS CURRENTLY APPROVED BY THE SECRETARY OF 11 12 HEALTH AND IN USE IN THE PRACTICE OF OPTOMETRY ON THE 13 EFFECTIVE DATE OF THIS SECTION SHALL BE DEEMED APPROVED UNDER

14 THIS SECTION.

15 (2) WITHIN 90 DAYS OF THE EFFECTIVE DATE OF THIS SECTION, THE BOARD SHALL SUBMIT A LIST OF DRUGS AUTHORIZED 16 UNDER THIS ACT TO THE SECRETARY OF HEALTH, WHO, IN 17 CONSULTATION WITH THE PHYSICIAN GENERAL, SHALL APPROVE OR 18 19 DISAPPROVE FOR GOOD CAUSE EACH DRUG. UPON FAILURE OF THE 20 SECRETARY OF HEALTH TO ACT WITHIN 90 DAYS OF RECEIPT OF THE LIST OF DRUGS, THE DRUGS SHALL BE DEEMED APPROVED FOR USE 21 2.2 UNDER THIS ACT.

23 (3) THE STATE BOARD OF OPTOMETRY SHALL PROVIDE THE SECRETARY OF HEALTH WITH LISTS OF ADDITIONAL DRUGS FOR USE 24 25 UNDER THIS ACT AFTER SUCH DRUGS ARE APPROVED BY THE FOOD AND DRUG ADMINISTRATION, AS PUBLISHED IN THE CODE OF FEDERAL 26 27 REGULATIONS. THE SECRETARY OF HEALTH, IN CONSULTATION WITH THE PHYSICIAN GENERAL, SHALL APPROVE OR DISAPPROVE FOR GOOD 28 29 CAUSE ANY SUCH DRUG WITHIN 90 DAYS OF THE RECEIPT OF THE LIST. UPON FAILURE OF THE SECRETARY OF HEALTH TO ACT WITHIN 30

- 10 -

1 90 DAYS, THE DRUGS SHALL BE DEEMED APPROVED FOR USE UNDER 2 THIS ACT.] 3 (4) ON AND AFTER THE EFFECTIVE DATE OF THIS PARAGRAPH, THE BOARD MAY APPROVE DRUGS FOR ONLY TOPICAL OR ORAL ROUTES 4 5 OF ADMINISTRATION, WITH THE EXCEPTION OF DRUGS CLASSIFIED AS 6 CHEMOTHERAPY DRUGS, FOR USE IN THE PRACTICE OF OPTOMETRY 7 AFTER THE DRUGS ARE APPROVED BY THE FOOD AND DRUG 8 ADMINISTRATION, AS PUBLISHED IN THE CODE OF FEDERAL 9 REGULATIONS. SECTION 6. EXEMPTIONS AND EXCEPTIONS. 10 \* \* \* 11 12 (B) THE BOARD SHALL PERMIT EXTERNS, WHO ARE [FOURTH YEAR] 13 OPTOMETRIC STUDENTS, TO PERFORM PROCEDURES AND TESTS FOR THE 14 SOLE PURPOSE OF INSTRUCTION AND EXPERIENCE UNDER THE DIRECT SUPERVISION AND CONTROL OF AN OPTOMETRIST LICENSED IN THIS 15 16 COMMONWEALTH IF THE PROCEDURES AND TESTS ARE WITHIN THE SCOPE OF PRACTICE OF THE OPTOMETRIST. NOTHING CONTAINED IN THIS ACT SHALL 17 18 BE CONSTRUED TO ENTITLE AN EXTERN TO PRACTICE OPTOMETRY. 19 \* \* \* SECTION 3. SECTION 8(A) OF THE ACT IS AMENDED BY ADDING A 20 21 PARAGRAPH TO READ: 2.2 SECTION 8. VIOLATIONS AND PENALTIES. (A) \* \* \* 23 24 (4) IT IS UNLAWFUL FOR AN OPTOMETRIST TO ADVERTISE A 25 SERVICE PROHIBITED UNDER THIS ACT. A PERSON CONVICTED OF 26 VIOLATING THIS PARAGRAPH COMMITS A SUMMARY OFFENSE AND SHALL, 27 FOR A FIRST OFFENSE, BE SUBJECT TO A FINE OF NOT MORE THAN 28 \$1,000. FOR A PERSON CONVICTED OF A SECOND OR SUBSEQUENT 29 VIOLATION, BE SUBJECT TO A FINE OF NOT LESS THAN \$2,000, AND 30 THE BOARD MAY IMPOSE A SUSPENSION OF THE PERSON'S LICENSE FOR

- 11 -

- 1 UP TO 30 DAYS, IN ADDITION TO THE FINE.
- 2 \* \* \*
- 3 SECTION 4. THIS ACT SHALL TAKE EFFECT IN 60 DAYS.